Trials / Terminated
TerminatedNCT04352413
A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy
An Open-label, Multi-center, Phase 2 Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open, multicenter phase II clinical study for PLM60. The primary aim of the study is to observe the initial efficacy of PLM60 in treatment of small cell lung cancer. The secondary aim is to explore the safety and PK characteristics of PLM60
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PLM60 | Administration: Intravenous infusion |
Timeline
- Start date
- 2020-06-18
- Primary completion
- 2022-01-30
- Completion
- 2022-04-29
- First posted
- 2020-04-20
- Last updated
- 2024-03-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04352413. Inclusion in this directory is not an endorsement.